keepitreal
Platinum Member
A new biological reagent is now available to labs around the UK and the world that will help them to set up and develop accurate diagnostic tests for coronavirus (COVID-19).
The reagent is intended to be used in tests that confirm whether an individual is currently infected with the virus.
The reagent can be used as a positive control for the testing systems used to detect the presence of COVID-19. A positive control is included in tests by means of a sample that contains a known amount of the coronavirus genetic material. This acts as a confirmatory sample that assures the test is working correctly.
The reagent is non-infectious genetic material from SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. An initial batch of 1,500 vials is available from the National Institute for Biological Standards and Control (NIBSC) with production of a further batch currently underway.
CONTENTS
Each vial contains 0.5 mL, frozen, non- infectious synthetic SARS-CoV-2 RNA packaged within Human Immunodeficiency virus type 1 (HIV-1) particles formulated in sterile Universal Buffer comprising 10 mM Tris-HCl (pH 7.4), 0.5% human serum albumin and 1% D-(+)- Trehalose dehydrate.
The source material used to prepare the research reagent 19/304 is a lentiviral vector (LVV)-based plasmid in which the HIV genes have been substituted with Wuhan-Hu-1 isolate (GenBank MN908947.3) SARS-CoV-2 using a similar approach as described in[1]. The SARS-CoV-2 genome has been divided into four overlapping fragments and inserted within the long terminal repeats of the LVV plasmid. Single nucleotide mutations have been randomly inserted in the SARS-CoV-2 sequences to prevent protein expression. The sequences of the four constructs have been deposited to GenBank: accession numbers MT299802, MT299803, MT299804, MT299805. The four LVV-SARS-CoV-2 constructs were each individually transfected into HEK293T/17 cells together with a HIV-1 packaging plasmid p8.9, kindly donated by Prof. D. Trono [2]. Particles contained in the supernatant of the transfected cells were purified by ultracentrifugation on a 20%- sucrose cushion and resuspended in universal buffer. Genome copies for each of the four types of particles were quantified using common sequences in the HIV-U5 region upstream of the SARS-CoV-2 sequences.
So, the clinical paper claiming as much from India was correct
So, why were they forced to withdraw it, which they did but filed a lawsuit
Using synthetic SARS 2 RNA and HIV virus particles
1 is created, 1 is real
Research reagent for SARS Cov 2
The reagent is intended to be used in tests that confirm whether an individual is currently infected with the virus.
The reagent can be used as a positive control for the testing systems used to detect the presence of COVID-19. A positive control is included in tests by means of a sample that contains a known amount of the coronavirus genetic material. This acts as a confirmatory sample that assures the test is working correctly.
The reagent is non-infectious genetic material from SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. An initial batch of 1,500 vials is available from the National Institute for Biological Standards and Control (NIBSC) with production of a further batch currently underway.
CONTENTS
Each vial contains 0.5 mL, frozen, non- infectious synthetic SARS-CoV-2 RNA packaged within Human Immunodeficiency virus type 1 (HIV-1) particles formulated in sterile Universal Buffer comprising 10 mM Tris-HCl (pH 7.4), 0.5% human serum albumin and 1% D-(+)- Trehalose dehydrate.
The source material used to prepare the research reagent 19/304 is a lentiviral vector (LVV)-based plasmid in which the HIV genes have been substituted with Wuhan-Hu-1 isolate (GenBank MN908947.3) SARS-CoV-2 using a similar approach as described in[1]. The SARS-CoV-2 genome has been divided into four overlapping fragments and inserted within the long terminal repeats of the LVV plasmid. Single nucleotide mutations have been randomly inserted in the SARS-CoV-2 sequences to prevent protein expression. The sequences of the four constructs have been deposited to GenBank: accession numbers MT299802, MT299803, MT299804, MT299805. The four LVV-SARS-CoV-2 constructs were each individually transfected into HEK293T/17 cells together with a HIV-1 packaging plasmid p8.9, kindly donated by Prof. D. Trono [2]. Particles contained in the supernatant of the transfected cells were purified by ultracentrifugation on a 20%- sucrose cushion and resuspended in universal buffer. Genome copies for each of the four types of particles were quantified using common sequences in the HIV-U5 region upstream of the SARS-CoV-2 sequences.
So, the clinical paper claiming as much from India was correct
So, why were they forced to withdraw it, which they did but filed a lawsuit
Using synthetic SARS 2 RNA and HIV virus particles
1 is created, 1 is real
Research reagent for SARS Cov 2
